Delcath Systems to Showcase Hepatic Delivery System at Society of Interventional Radiology 2026 Meeting
Delcath Systems, Inc., an interventional oncology company, is set to participate in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting in Toronto, Canada, from April 11-15, 2026. The company will feature its Hepatic Delivery System (HDS) for percutaneous hepatic perfusion in three presentations. Dr. Eric Wehrenberg-Klee from Massachusetts General Hospital will discuss his user experience with HEPZATO at the SIR Innovation Hub. Dr. David Eschelman from Thomas Jefferson University and Dr. Mustafa Ege Seker from the University of Wisconsin will present their clinical experiences with the system for treating liver metastases from uveal melanoma. Delcath's HEPZATO KIT, approved by the FDA, is designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. 
